Muscle-invasive bladder cancer represents a critical oncologic entity with a notorious propensity for progression and metastasis. Traditional diagnostic modalities, predominantly imaging and tissue biopsies, present limitations including invasiveness, sampling bias, and inability to capture the temporal heterogeneity of the tumor. The integration of ctDNA analysis circumvents many of these challenges by offering a minimally invasive method to obtain real-time molecular snapshots of tumor genomics through a simple blood draw. This modality holds promise in providing dynamic insights into tumor burden, mutational landscape, and clonal evolution, which are imperative for precision medicine.

The biological foundation of ctDNA stems from apoptotic and necrotic tumor cells releasing fragmented DNA into the bloodstream. This circulating fraction carries tumor-specific genetic alterations such as point mutations, copy number variations, and methylation patterns, which serve as molecular fingerprints. State-of-the-art technologies enable the isolation and high-sensitivity quantification of ctDNA, facilitating an unparalleled window into tumor biology. For MIBC, where early detection of residual disease post-neoadjuvant chemotherapy or surgical resection is critical, ctDNA detection becomes a powerful tool for risk stratification and surveillance.

Translating ctDNA detection into clinical decision-making involves sophisticated genomic profiling and bioinformatic algorithms. By identifying actionable mutations within ctDNA, clinicians can direct therapies that precisely target the evolving tumor subclones. This shift from empirical treatment towards biomarker-driven interventions represents a paradigm change, enhancing therapeutic efficacy while minimizing unnecessary toxicity. Notably, in MIBC, where conventional chemotherapy and radical cystectomy remain standard, ctDNA-guided therapies can identify candidates for emerging targeted therapies or immunotherapy, thereby personalizing care pathways.

One of the paramount challenges in ctDNA applications lies in assay sensitivity and specificity. Given the variable and often low fraction of ctDNA circulating in plasma, particularly in early-stage or minimal residual disease settings, technological advancements such as digital droplet PCR (ddPCR), next-generation sequencing (NGS), and error-corrected sequencing are essential. These methodologies amplify minute quantities of ctDNA while discriminating true tumor-derived alterations from background noise or clonal hematopoiesis. For MIBC, achieving reliable ctDNA detection thresholds is crucial for integrating this biomarker into routine clinical workflows.

Longitudinal monitoring of ctDNA provides a dynamic biomarker for treatment response and early relapse detection. In the context of MIBC, serial ctDNA measurements can reveal molecular residual disease (MRD) status following definitive therapy. Persistent or rising ctDNA levels often precede radiographic evidence of disease recurrence by months, affording a critical window for pre-emptive therapeutic interventions. This temporal sensitivity positions ctDNA as a game-changer in post-treatment surveillance, facilitating timely modifications in treatment strategy based on tumor resurgence activity.

Molecular heterogeneity and clonal evolution constitute central impediments to effective MIBC management. The tumor genome in MIBC evolves under selective pressures imposed by therapy, enabling resistant subclones to emerge. ctDNA profiling captures this evolutionary trajectory, furnishing insights into resistance mechanisms such as mutations in DNA damage repair genes or alterations in immune checkpoint pathways. Understanding these alterations empowers oncologists to anticipate therapeutic resistance and adapt treatments, thereby circumventing relapse and prolonging patient survival.

Integrating ctDNA analysis with other emerging biomarkers and clinical parameters may enhance the precision of personalized therapy. For example, combining ctDNA mutational burden assessments with urinary biomarkers, imaging findings, and patient-specific factors can synergistically delineate high-risk profiles. This multi-dimensional approach fosters a holistic perspective on MIBC tumor biology, enabling the design of individualized treatment regimens that optimize efficacy while preserving quality of life.

The current clinical trials landscape reflects a burgeoning interest in ctDNA-guided therapeutic strategies for MIBC. Recent studies incorporate ctDNA assays as integral components of trial design to evaluate neoadjuvant chemotherapy response, guide adjuvant therapy selection, and monitor immune checkpoint inhibitor efficacy. Early data suggest that ctDNA-positive patients might benefit from intensified therapeutic regimens, while ctDNA-negative individuals may avoid overtreatment. These findings hold profound implications for resource allocation and health economics in oncology practice.

Despite its promise, ctDNA implementation faces barriers including standardization of assays, regulatory approvals, and integration into existing diagnostic pathways. Harmonization of ctDNA analysis protocols and establishment of universally accepted thresholds are essential to ensure reproducibility and comparability across institutions. Moreover, educating clinicians about the interpretation and clinical utility of ctDNA results is pivotal to foster widespread adoption and maximize patient benefit in MIBC care.

Ethical considerations also come to the forefront with ctDNA-driven personalized therapy. The detection of minimal residual disease or preclinical relapse raises challenges regarding patient counseling, psychological impact, and decision-making. Balancing the benefits of early intervention against the risks of overtreatment requires nuanced clinical judgment and patient-centered communication strategies. Future protocols must incorporate frameworks to navigate these complex ethical landscapes in the context of ctDNA-guided MIBC management.

From a technological standpoint, the future of ctDNA analysis may align with advancements such as artificial intelligence and machine learning. These tools can integrate vast datasets from ctDNA sequencing with clinical variables to generate predictive models and treatment algorithms. The fusion of molecular diagnostics with computational analytics promises to accelerate precision oncology, enabling real-time adaptive therapy for MIBC with unprecedented granularity and accuracy.

Particularly intriguing is the potential for ctDNA to uncover novel therapeutic targets in MIBC. Deep sequencing of ctDNA can reveal rare mutations or epigenetic changes not previously identified through tissue biopsy. This expands the therapeutic arsenal, opening avenues for the development of drugs targeting previously unrecognized vulnerabilities within the tumor genome. Consequently, ctDNA research may catalyze a new wave of drug discovery and clinical trial innovations focused on MIBC.

Furthermore, ctDNA may serve a role beyond individualized therapy direction, contributing to population-level cancer control efforts. Screening high-risk populations such as smokers or those with prior bladder cancer history using ctDNA assays could facilitate early MIBC detection, drastically shifting morbidity and mortality patterns. Public health initiatives incorporating liquid biopsy technology could redefine bladder cancer screening paradigms, rendering early-stage diagnosis more accessible and less invasive.

In conclusion, the integration of circulating tumor DNA analysis into the diagnostic and therapeutic continuum for muscle-invasive bladder cancer signifies a watershed moment in oncology. By harnessing the molecular insights afforded by ctDNA, clinicians are now equipped to transition from a one-size-fits-all approach to a highly personalized model of care that dynamically adapts to tumor evolution. While challenges remain, ongoing innovations and clinical validation efforts are rapidly paving the way for ctDNA-guided therapies to become standard practice, promising improved outcomes and individualized hope for patients confronting MIBC.

Subject of Research: Personalized therapy strategies guided by circulating tumor DNA (ctDNA) in muscle-invasive bladder cancer.

Article Title: From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer.

Article References:
Suelmann, B.B.M., van der Heijden, M.S. From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01113-y

Image Credits: AI Generated

Over the past decade, the Human Islet Research Network (HIRN), established by the National Institute of Diabetes and Digestive and Kidney Diseases in 2014, has made substantial strides in unraveling the complexities of type 1 diabetes pathogenesis. Spearheaded by City of Hope’s John Kaddis, the interdisciplinary HIRN consortium has developed innovative in vitro and in vivo systems that elucidate beta cell behavior within their native microenvironment. These advances allow scientists to model disease progression more accurately, employing novel technologies to dissect beta cell loss, immune interactions, and mechanisms of cell replacement. Despite these advancements, critical gaps remain in understanding the precise triggers for autoimmune beta cell destruction and how best to intercept these processes before the onset of clinical disease. The network emphasizes shared data platforms and collaborative training to foster cross-disciplinary solutions aimed at preventing and ultimately curing type 1 diabetes.

Emerging epidemiological evidence highlights the impact of obesity on multiple myeloma progression, particularly in individuals with the precursor lesion monoclonal gammopathy of undetermined significance (MGUS). Research led by Lawrence Liu at City of Hope meticulously analyzed longitudinal body mass index (BMI) data from nearly 22,500 MGUS patients to quantify the risk attributed to sustained elevated BMI. Their findings reveal a compelling correlation between prolonged exposure to overweight or obese BMI ranges and an increased likelihood of progression to full-blown multiple myeloma. Participants maintaining a BMI above 25 after diagnosis demonstrated a significantly elevated risk of malignancy evolution, underscoring the crucial importance of weight management in mitigating cancer risk. This study represents a paradigm shift in recognizing metabolic factors as modifiable determinants in hematologic cancer progression.

In the realm of metastatic colorectal cancer (mCRC), precision medicine continues to evolve with sophisticated biomarker-driven approaches to guide therapeutic decisions. Investigators at City of Hope, led by Ajay Goel, validated a revolutionary liquid biopsy platform known as EXONERATE to predict patient responses to epidermal growth factor receptor (EGFR) inhibitors, specifically panitumumab and cetuximab. Employing genome-wide small RNA sequencing of circulating exosomes and cell-free microRNAs, the assay identifies molecular signatures indicative of therapeutic efficacy. Crucially, this technology accounts for tumor heterogeneity associated with primary tumor sidedness, a known determinant of EGFR inhibitor response. The assay demonstrated robust predictive value for progression-free and overall survival across diverse patient populations, offering an unprecedented non-invasive tool for real-time treatment stratification in mCRC management.

Immune checkpoint blockade has transformed oncologic care, yet the heterogeneity of patient response remains a formidable challenge. Targeting this, Kelly Mahuron and colleagues at City of Hope embarked on an intricate molecular characterization of tumor infiltrating lymphocytes (TILs) within advanced melanoma samples to identify biomarkers predictive of anti-PD-1 antibody efficacy. Their seminal work employing single-cell RNA sequencing delineated a unique CD8+ TIL subset expressing high levels of PD-1 and CTLA-4 receptors, termed CP^Hi TILs. Patients harboring ≥20% CP^Hi TILs exhibited markedly improved objective response rates and survival outcomes following PD-1 monotherapy. This pioneering biomarker assay holds transformative potential for refining patient selection in immunotherapy, enabling clinicians to tailor treatments based on intratumoral immune cell phenotypes and thereby maximizing therapeutic benefit while minimizing unnecessary toxicity.

Cardiotoxicity remains a critical long-term concern for pediatric cancer survivors, whose growing population faces significant risks for treatment-related cardiovascular disease. A recent scientific statement from the American Heart Association, co-authored by City of Hope’s Saro Armenian, addresses emerging cardio-oncology challenges in this vulnerable group. Reflecting on decades of research, the statement underscores the deleterious effects of anthracycline chemotherapy and chest radiotherapy—cornerstones of pediatric oncology—on cardiac function. Advances in dose optimization, cardioprotective agents, and modern radiotherapy techniques have ameliorated some risks but novel therapies, including small-molecule inhibitors and immunotherapies, introduce new cardiotoxicity profiles. The comprehensive review advocates for equitable long-term surveillance, rehabilitation through structured physical activity, and seamless transition from pediatric to adult cardiology care to improve cardiovascular outcomes in childhood cancer survivors.

In efforts to counteract disease progression in chronic myeloid leukemia (CML), researchers at City of Hope led by Bin Zhang and Guido Marcucci have uncovered a novel immune-evasion mechanism operative during the transition to blast crisis (BC). Their study, published in Nature Communications, elucidates how acquired deficiency of microRNA miR-142 precipitates loss of cytotoxic T cells essential for anti-leukemic immunity. The miR-142 deficit simultaneously facilitates leukemic stem cell immune escape, thereby accelerating malignant transformation. Remarkably, the team developed a synthetic miR-142 mimic, M-miR-142, capable of restoring immune surveillance when administered alone or alongside monoclonal antibodies and tyrosine kinase inhibitors. Preclinical trials in murine models demonstrated prolonged survival, offering a promising therapeutic avenue to forestall BC progression and improve patient prognosis through immune modulation.

City of Hope also proudly celebrates the outstanding achievements of its scientific community. Notably, Dr. Ravi Salgia’s recognition as a Highly Ranked Scholar — Lifetime — for contributions to lung cancer research highlights the institution’s leadership. The 2025 American Association for Cancer Research (AACR) annual meeting further honored City of Hope researchers including Daniel D. Von Hoff for his unwavering dedication to cancer research and clinical care, Enrique Velazquez Villarreal for his minority scholar award recognition, and emerging scientists Kimya Karimi, Francisco Carranza, Eric Medina, and Isaac Bishara for their promising work in cancer research. These accolades attest to the vibrant and diverse scientific talent driving innovation at City of Hope.

In funding news, Ling Li, Ph.D., was awarded a prestigious $3.58 million National Cancer Institute grant for her innovative study targeting adenosine monophosphate (AMP) synthesis pathways to overcome resistance to BH3 mimetics in acute myeloid leukemia (AML). This research holds potential to surmount one of the major obstacles in AML therapy—the development of drug resistance—by exploiting metabolic vulnerabilities within leukemic cells, thereby enhancing the efficacy of pro-apoptotic agents.

City of Hope’s integrated research and clinical care model remains a cornerstone of its mission to revolutionize outcomes for patients afffected with cancer and diabetes. Its National Cancer Institute-designated comprehensive cancer center, consistently ranked among the top five in the United States, exemplifies excellence in multidisciplinary innovation, combining translational research, cutting-edge clinical trials, and an expansive network of care delivery. Through synergy with affiliated organizations such as the Translational Genomics Research Institute and AccessHope™, City of Hope continues to pioneer breakthroughs — from synthetic insulin production to monoclonal antibody therapeutics — redefining the standard of medical care.

Harnessing advanced molecular technologies, collaborative scientific inquiry, and clinical acumen, City of Hope’s researchers pave the way for precision medicine and immunotherapy strategies tailored to individual patient biology. Their recent discoveries in disease biomarkers, immune modulation, and metabolic regulation not only elucidate fundamental disease processes but also herald novel therapeutic paradigms. As the institution fuels this momentum, the prospects for improved prevention, diagnostic, and treatment modalities across oncology and metabolic disease grow exponentially, offering renewed hope for patients worldwide.

Subject of Research: Diabetes, Multiple Myeloma, Metastatic Colorectal Cancer, Immune Checkpoint Inhibitor Response, Pediatric Cardiovascular Toxicity, Chronic Myeloid Leukemia, Cancer Therapeutics, Biomarkers

Article Title: City of Hope Research Spotlight: Advances in Diabetes, Cancer Biology, Immunotherapy, and Survivorship

News Publication Date: 2025

Web References:

• City of Hope Research Spotlight Feed: https://www.cityofhope.org/about-city-of-hope/newsroom/research-spotlight/feed
• Diabetes Journal Article: https://doi.org/10.2337/db25-0097
• JAMA Network Open Paper: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2830028
• Clinical Cancer Research Paper: https://aacrjournals.org/clincancerres/article-abstract/31/6/1002/753268/An-Exosome-Based-Liquid-Biopsy-Predicts-Depth-of
• Cancer Research Paper: https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-23-3918/753249/Single-Cell-Analyses-Reveal-a-Functionally
• Circulation Review Paper: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001308
• Nature Communications Paper: https://www.nature.com/articles/s41467-025-56383-y

References: Included within the text as links to primary scientific publications.

Keywords: Cancer research, Diabetes research, Multiple Myeloma, Liquid biopsy, EGFR inhibitors, Immune checkpoint inhibitors, Pediatric cardio-oncology, Chronic myeloid leukemia, Biomarkers, Immunotherapy, Molecular diagnostics